Nuclear receptors, transcription factors linking lipid metabolism and immunity: The case of peroxisome proliferator-activated receptor gamma

European Journal of Clinical Investigation

Volumn 38, Issue 10, 2008, Pages 695-707

  Varga, T ^a,c   Nagy, L ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b UNIVERSITY OF DEBRECEN   (Hungary)

^c INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Dendritic cells; Inflammation; Intestinal epithelial cells; Macrophages; Metabolism; PPAR

Indexed keywords

CELL NUCLEUS RECEPTOR; FATTY ACID; GLITAZONE DERIVATIVE; HORMONE RECEPTOR; LIPOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; ROSIGLITAZONE; TRANSCRIPTION FACTOR;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTATION; ATHEROSCLEROSIS; AUTOIMMUNITY; CELL FUNCTION; CELL METABOLISM; CHRONIC INFLAMMATION; COLITIS; COLON CANCER; CYTOLOGY; DENDRITIC CELL; DRUG MECHANISM; EPITHELIUM CELL; GENE EXPRESSION; GENOME; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INSULIN RESISTANCE; INTESTINE EPITHELIUM; LIPID METABOLISM; LIPID TRANSPORT; MACROPHAGE; MAMMAL CELL; MOLECULAR SENSOR; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS; DENDRITIC CELLS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY; LIPID METABOLISM; MACROPHAGES; PPAR GAMMA; SIGNAL TRANSDUCTION;

EID: 52149096070     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2008.02022.x     Document Type: Review

References (74)

1. Dreyer C, Krey G, Keller H, Givel F, Helftenbein G, Wahli W. Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors. Cell 1992 68 : 879 87.
2. Rosen ED, Spiegelman BM. PPARγ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001 276 : 37731 4.
3. Heikkinen S, Auwerx J, Argmann CA. PPARγ in human and mouse physiology. Biochim Biophys Acta 2007 1771 : 999 1013.
4. Kliewer SA, Lenhard JM, Willson TM, Patel I, Morris DC, Lehmann JM. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 1995 83 : 813 9.
5. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K et al. The nuclear receptor superfamily: the second decade. Cell 1995 83 : 835 9.
6. Zhu Y, Qi C, Korenberg JR, Chen XN, Noya D Rao MS et al. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: alternative promoter use and different splicing yield two mPPARγ isoforms. Proc Natl Acad Sci USA 1995 92 : 7921 5.
7. 2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995 83 : 803 12.
8. Huang JT, Welch JS, Ricote M, Binder CJ, Willson TM, Kelly C et al. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999 400 : 378 82.
9. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 1998 93 : 229 40.
10. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 2005 437 : 759 63.
11. Pascual G, Glass CK. Nuclear receptors versus inflammation: mechanisms of transrepression. Trends Endocrinol Metab 2006 17 : 321 7.
12. 2 inhibits multiple steps in the NF-κB signaling pathway. Proc Natl Acad Sci USA 2000 97 : 4844 9.
13. κB kinase. Nature 2000 403 : 103 8.
14. Szatmari I, Torocsik D, Agostini M, Nagy T, Gurnell M, Barta E et al. PPARγ regulates the function of human dendritic cells primarily by altering lipid metabolism. Blood 2007 110 : 3271 80.
15. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006 444 : 860 7.
16. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M et al. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 2001 293 : 1673 7.
17. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR et al. PPARγ is required for placental, cardiac, and adipose tissue development. Mol Cell 1999 4 : 585 95.
18. Wan Y, Chong LW, Evans RM. PPAR-γ regulates osteoclastogenesis in mice. Nat Med 2007 13 : 1496 503.
19. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S et al. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 2002 22 : 2607 19.
20. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003 3 : 23 35.
21. Nambiar PR, Girnun G, Lillo NA, Guda K, Whiteley HE, Rosenberg DW. Preliminary analysis of azoxymethane induced colon tumors in inbred mice commonly used as transgenic/knockout progenitors. Int J Oncol 2003 22 : 145 50.
22. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, Morel CR, Subramanian V, Mukundan L et al. Macrophage-specific PPARγ controls alternative activation and improves insulin resistance. Nature 2007 447 : 1116 20.
23. Hevener AL, Olefsky JM, Reichart D, Nguyen MT, Bandyopadyhay G, Leung HY et al. Macrophage PPARγ is required for normal skeletal muscle and hepatic insulin sensitivity and full antidiabetic effects of thiazolidinediones. J Clin Invest 2007 117 : 1658 69.
24. 2. J Neuroimmunol 2006 178 : 76 86.
25. Dubuquoy L, Rousseaux C, Thuru X, Peyrin-Biroulet L, Romano O, Chavatte P et al. PPARγ as a new therapeutic target in inflammatory bowel diseases. Gut 2006 55 : 1341 9.
26. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell 1994 79 : 1147 56.
27. Tamori Y, Masugi J, Nishino N, Kasuga M. Role of peroxisome proliferator-activated receptor-γ in maintenance of the characteristics of mature 3T3-L1 adipocytes. Diabetes 2002 51 : 2045 55.
28. Rosen ED, Sarraf P, Troy AE, Bradwin G, Moore K, Milstone DS et al. PPARγ is required for the differentiation of adipose tissue in vivo and in vitro. Mol Cell 1999 4 : 611 7.
29. Gerhold DL, Liu F, Jiang G, Li Z, Xu J, Lu M et al. Gene expression profile of adipocyte differentiation and its regulation by peroxisome proliferator-activated receptor-γ agonists. Endocrinology 2002 143 : 2106 18.
30. Rosen ED, MacDougald OA. Adipocyte differentiation from the inside out. Nat Rev Mol Cell Biol 2006 7 : 885 96.
31. Sears IB, MacGinnitie MA, Kovacs LG, Graves RA. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor γ. Mol Cell Biol 1996 16 : 3410 9.
32. Schoonjans K, Peinado-Onsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S et al. PPARα and PPARγ activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J 1996 15 : 5336 48.
33. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol 2008 9 : 367 77.
34. Scherer PE, Williams S, Fogliano M, Baldini G, Lodish HF. A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 1995 270 : 26746 9.
35. Fried SK, Bunkin DA Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab 1998 83 : 847 50.
36. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993 259 : 87 91.
37. Sartipy P, Loskutoff DJ. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003 100 : 7265 70.
38. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 1996 2 : 800 3.
39. He W, Barak Y, Hevener A, Olson P, Liao D, Le J et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA 2003 100 : 15712 7.
40. Norris AW, Chen L, Fisher SJ, Szanto I, Ristow M, Jozsi AC et al. Muscle-specific PPARγ-deficient mice develop increased adiposity and insulin resistance but respond to thiazolidinediones. J Clin Invest 2003 112 : 608 18.
41. Agostini M, Schoenmakers E, Mitchell C, Szatmari I, Savage D, Smith A et al. Non-DNA binding, dominant-negative, human PPARγ mutations cause lipodystrophic insulin resistance. Cell Metab 2006 4 : 303 11.
42. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003 112 : 1796 808.
43. Zhang B, Berger J, Hu E, Szalkowski D, White-Carrington S, Spiegelman BM et al. Negative regulation of peroxisome proliferator-activated receptor-γ gene expression contributes to the antiadipogenic effects of tumor necrosis factor-α. Mol Endocrinol 1996 10 : 1457 66.
44. Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998 391 : 79 82.
45. Jiang C, Ting AT, Seed B. PPAR-γ agonists inhibit production of monocyte inflammatory cytokines. Nature 1998 391 : 82 6.
46. Natarajan C, Muthian G, Barak Y, Evans RM, Bright JJ. Peroxisome proliferator-activated receptor-γ-deficient heterozygous mice develop an exacerbated neural antigen-induced Th1 response and experimental allergic encephalomyelitis. J Immunol 2003 171 : 5743 50.
47. Niino M, Iwabuchi K, Kikuchi S, Ato M, Morohashi T, Ogata A et al. Amelioration of experimental autoimmune encephalomyelitis in C57BL/6 mice by an agonist of peroxisome proliferator-activated receptor-γ. J Neuroimmunol 2001 116 : 40 8.
48. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK. PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proc Natl Acad Sci USA 2003 100 : 6712 7.
49. Ricote M, Welch JS, Glass CK. Regulation of macrophage gene expression by the peroxisome proliferator-activated receptor-gamma. Horm Res 2000 54 : 275 80.
50. Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P, Evans RM. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001 7 : 48 52.
51. Valledor AF, Ricote M. Nuclear receptor signaling in macrophages. Biochem Pharmacol 2004 67 : 201 12.
52. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986 232 : 34 47.
53. Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M et al. Terminal differentiation of human breast cancer through PPARγ. Mol Cell 1998 1 : 465 70.
54. Nicholson AC, Han J, Febbraio M, Silversterin RL, Hajjar DP. Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis. Ann N Y Acad Sci 2001 947 : 224 8.
55. Podrez EA, Febbraio M, Sheibani N, Schmitt D, Silverstein RL, Hajjar DP et al. Macrophage scavenger receptor CD36 is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. J Clin Invest 2000 105 : 1095 108.
56. Szanto A, Benko S, Szatmari I, Balint BL, Furtos I, Ruhl R et al. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages. Mol Cell Biol 2004 24 : 8154 66.
57. Faveeuw C, Fougeray S, Angeli V, Fontaine J, Chinetti G, Gosset P et al. Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells. FEBS Lett 2000 486 : 261 6.
58. Caton ML, Smith-Raska MR, Reizis B. Notch-RBP-J signaling controls the homeostasis of CD8- dendritic cells in the spleen. J Exp Med 2007 204 : 1653 64.
59. Bush CR, Havens JM, Necela BM, Su W, Chen L, Yanagisawa M et al. Functional genomic analysis reveals cross-talk between peroxisome proliferator-activated receptor γ and calcium signaling in human colorectal cancer cells. J Biol Chem 2007 282 : 23387 401.
60. Drori S, Girnun GD, Tou L, Szwaya JD, Mueller E, Xia K et al. Hic-5 regulates an epithelial program mediated by PPARγ. Genes Dev 2005 19 : 362 75.
61. Kohno H, Yoshitani S, Takashima S, Okumura A, Hosokawa M, Yamaguchi N et al. Troglitazone, a ligand for peroxisome proliferator-activated receptor γ, inhibits chemically-induced aberrant crypt foci in rats. Jpn J Cancer Res 2001 92 : 396 403.
62. Osawa E, Nakajima A, Wada K, Ishimine S, Fujisawa N, Kawamori T et al. Peroxisome proliferator-activated receptor γ ligands suppress colon carcinogenesis induced by azoxymethane in mice. Gastroenterology 2003 124 : 361 7.
63. Min/+ mice. Nat Med 1998 4 : 1053 7.
64. Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998 4 : 1058 61.
65. Niho N, Takahashi M, Kitamura T, Shoji Y, Itoh M, Noda T et al. Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003 63 : 6090 5.
66. Girnun GD, Smith WM, Drori S, Sarraf P, Mueller E, Eng C et al. APC-dependent suppression of colon carcinogenesis by PPARγ. Proc Natl Acad Sci USA 2002 99 : 13771 6.
67. Min/+ mice. Int J Cancer 2006 119 : 2339 46.
68. Chen L, Bush CR, Necela BM, Su W, Yanagisawa M, Anastasiadis PZ et al. RS5444, a novel PPARγ agonist, regulates aspects of the differentiated phenotype in nontransformed intestinal epithelial cells. Mol Cell Endocrinol 2006 251 : 17 32.
69. Guan YF, Zhang YH, Breyer RM, Davis L, Breyer MD. Expression of peroxisome proliferator-activated receptor gamma (PPARγ) in human transitional bladder cancer and its role in inducing cell death. Neoplasia 1999 1 : 330 9.
70. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor γ in non-small cell lung cancer. Cancer Res 2000 60 : 1129 38.
71. Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y. Activation of peroxisome proliferator-activated receptor γ by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 2000 60 : 5558 64.
72. Elnemr A, Ohta T, Iwata K, Ninomia I, Fushida S, Nishimura G et al. PPARγ ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol 2000 17 : 1157 64.
73. Kawa S, Nikaido T, Unno H, Usuda N, Nakayama K, Kiyosawa K. Growth inhibition and differentiation of pancreatic cancer cell lines by PPARγ ligand troglitazone. Pancreas 2002 24 : 1 7.
74. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferator- activated receptor γ ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999 274 : 9116 21.